Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance
Phytomedicine · 2026-05 · 154 · 158016
DOI: 10.1016/j.phymed.2026.158016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026-05. Verfasst von Ke-Fan Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Shenyang Medical College, Shenyang 110034, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Amyloid Precursor Protein Secretases, Paclitaxel, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Natural Science Foundation of China National Outstanding Youth Science Fund Project, Liaoning Provincial Natural Science Foundation.
Abstract (Originalsprache)
BACKGROUND: Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer. Paclitaxel (Taxol) serves as a first-line chemotherapeutic agent, but the emergence of drug resistance often limits its clinical efficacy. Bioactive compounds with anticancer potential and reduced toxicity have thus gained increasing research interest. Erythrinin C (EC), known for its favorable drug-like properties and accessible sourcing has attracted significant attention. However, its mechanism of action and role in modulating chemotherapy resistance remain unclear. PURPOSE: This study aimed to evaluate the antitumor effects of EC on TNBC both in vivo and in vitro, and to investigate its ability to reverse of drug resistance in TNBC/Taxol cells either alone or in combination with Taxol. METHODS: The crystal structure of the γ-secretase protein was obtained from the Protein Data Bank (RCSB PDB), and a pharmacophore model was constructed based on its natural small-molecule ligands. Pharmacophore-based screening was performed across traditional Chinese medicine and natural product database to identify potential drug candidates. Confirm the interaction target between EC and γ-secretase was validated, and the biological effects, genetic influences, and in vivo activity of EC targeting γ-secretase were assessed through in vitro and in vivo experiments. RESULTS: EC was identified as a γ-secretase inhibitor and was shown to suppress TNBC cell proliferation and migration in vitro. Genetic modulation of PSEN-1 in MDA-MB-231 cells revealed that low PSEN-1 expression inhibits the malignant phenotype of TNBC cells. Pharmacological evaluation confirmed that EC treatment effectively slows TNBC progression. Furthermore, EC effectively reversed Taxol resistance in TNBC/Taxol cells. In vivo experiments further demonstrated that the combination of EC and Taxol significantly inhibited xenograft tumor growth. CONCLUSION: EC acts as a natural γ-secretase inhibitor that exerts significant anti-TNBC activity in both in vitro and in vivo by targeting PSEN-1 subunit. It also reverses TNBC/Taxol resistance at both cellular and animal levels, highlighting its promising and potential as a novel targeted therapeutic candidate for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Shenyang Medical College, Shenyang 110034, China.
- Department of Pathology, General Hospital of Northern Theater Command, Shenyang 110015, China.
- Science and Experimental Research Center of Shenyang Medical College, No 146 Huanghe North Street, Yuhong District, Shenyang City 110034, Liaoning Province, China.
- Science and Experimental Research Center of Shenyang Medical College, No 146 Huanghe North Street, Yuhong District, Shenyang City 110034, Liaoning Province, China. Electronic address: zhanglu0412@symc.edu.cn.
- Science and Experimental Research Center of Shenyang Medical College, No 146 Huanghe North Street, Yuhong District, Shenyang City 110034, Liaoning Province, China. Electronic address: xuqiandoctor@sina.com.
- Department of Endocrinology, General Hospital of Northern Theater Command, Shenyang 110015, China. Electronic address: kandy15@126.com.
Förderung
- National Natural Science Foundation of China
- National Natural Science Foundation of China National Outstanding Youth Science Fund Project
- Liaoning Provincial Natural Science Foundation
Zitieren
APA
Yang, K. F., Wang, D., Yao, K., Xu, R., Hu, L. Z., Liu, Y. Y., Zhang, L., Xu, Q., Yang, X., Zhou, M. S., & Jia, H. (2026). Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance. Phytomedicine, 154, 158016. https://doi.org/10.1016/j.phymed.2026.158016
Vancouver
Yang KF, Wang D, Yao K, Xu R, Hu LZ, Liu YY, et al. Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance. Phytomedicine. 2026;154:158016. doi:10.1016/j.phymed.2026.158016
BibTeX
@article{Yang2026,
author = {Yang, Ke-Fan and Wang, Di and Yao, Kuo and Xu, Ran and Hu, Li-Zhi and Liu, Yue-Yang and Zhang, Lu and Xu, Qian and Yang, Xin and Zhou, Ming-Sheng and Jia, Hui},
title = {Naturally derived Erythrinin C targets γ-secretase signaling to suppress triple-negative breast cancer progression and reverse paclitaxel resistance},
journal = {Phytomedicine},
year = {2026},
volume = {154},
pages = {158016},
doi = {10.1016/j.phymed.2026.158016}
}
EUVIMED